title: Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries).
abstract: This study evaluated and compared the efficacy of sirolimus-eluting stents (n = 145 patients) with that of paclitaxel-eluting stents (n = 148 patients) in 293 consecutive unselected patients who had diabetes mellitus. Baseline clinical characteristics and presentations were similar: mean age of 64 years, 50% presented with unstable angina or myocardial infarction, and 66% had multivessel disease. Angiographic and procedural characteristics differed, with more complex lesions and more vein grafts managed in the paclitaxel-eluting stent group. Overall mean stented length was 46 +/- 32 mm. There were no differences in unadjusted outcomes by stent type (1-year major adverse cardiac event rates of 20.4% for sirolimus-eluting stents vs 15.6% for paclitaxel-eluting stents, p = 0.12) or when adjusted for multivariate predictors (adjusted hazard ratio 0.68, 95% confidence interval 0.37 to 1.24, p = 0.21). Independent predictors of outcome in patients who had diabetes mellitus were stenting of the left main artery, stenting of the left anterior descending artery, creatinine clearance, and female gender. Patients who required insulin had a significantly higher, crude major adverse cardiac event rate at 1 year compared with those who used oral agents, but this rate became nonsignificant when adjusted for independent predictors of outcome.
authors.affiliation: Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Andrew T L
authors.initials: AT
authors.lastname: Ong
authors.forename: Jiro
authors.initials: J
authors.lastname: Aoki
authors.forename: Carlos A G
authors.initials: CA
authors.lastname: van Mieghem
authors.forename: Gaston A
authors.initials: GA
authors.lastname: Rodriguez Granillo
authors.forename: Marco
authors.initials: M
authors.lastname: Valgimigli
authors.forename: Keiichi
authors.initials: K
authors.lastname: Tsuchida
authors.forename: Karel
authors.initials: K
authors.lastname: Sonnenschein
authors.forename: Evelyn
authors.initials: E
authors.lastname: Regar
authors.forename: Willem J
authors.initials: WJ
authors.lastname: van der Giessen
authors.forename: Peter P T
authors.initials: PP
authors.lastname: de Jaegere
authors.forename: Georgios
authors.initials: G
authors.lastname: Sianos
authors.forename: Eugene P
authors.initials: EP
authors.lastname: McFadden
authors.forename: Pim J
authors.initials: PJ
authors.lastname: de Feyter
authors.forename: Ron T
authors.initials: RT
authors.lastname: van Domburg
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy*; D048909:Diabetes Complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D009426:Netherlands; D017239:Paclitaxel / Q000008:administration & dosage*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus